Canaccord reiterates Buy on 10X Genomics stock after acquisition

Canaccord reiterated a Buy rating and $32 price target on 10X Genomics after its acquisition of Proteintech Genomics, a deal aimed at expanding multimodal analysis and proteomics capabilities. The firm said integration risk appears limited and the near-term financial impact should be modest, while the acquisition strengthens 10X’s multiomic strategy ahead of the Atera launch in 2H 2026. The stock trades at $30.59, up 187% over the past year, though InvestingPro flagged valuation concerns.

Analysis

This is less a near-term earnings event than a strategic moat extension. The acquisition improves TXG’s odds of becoming the default platform for cross-modality workflows, which matters because once labs standardize on a sample-prep and data-analysis stack, switching costs become more about workflow retraining than reagent pricing. The second-order effect is that TXG can pull proteomics into the same procurement decision as transcriptomics, increasing wallet share before rivals can bundle a comparable end-to-end offering.

The competitive read-through is sharper for ILMN than the headline implies. If ILMN’s spatial push is perceived as a credible alternative, TXG will likely respond by accelerating ecosystem partnerships and bundling more aggressively, which can pressure gross margin in the next 2-4 quarters even if revenue growth improves. The more important issue is that the acquisition reduces the probability that proteomics becomes a standalone point solution; that is structurally bearish for smaller tool vendors relying on “best-of-breed” fragmentation.

The market is probably underestimating the timing asymmetry. Financial impact is likely muted this year, but platform validation events can re-rate the stock well before revenue inflects, especially if Atera and adjacent launches create a visible multi-year installed-base upgrade path. The main bear case is not integration failure; it is that AI-driven computational biology substitutes for some experimental demand faster than TXG can monetize the expanded workflow, which would cap multiple expansion.

MSFT’s AI noise is a sentiment headwind rather than a fundamental threat unless it translates into actual budget reallocation at pharma and academic buyers. If the stock pullback was driven by fears that AI compresses demand for spatial/proteomic tools, that looks overstated on a 6-12 month horizon: AI can accelerate target discovery, but it still needs wet-lab validation and tissue context. The contrarian opportunity is that the market may be mixing up discovery software disruption with assay demand destruction.

Key Decisions for Investors

• Go long TXG on any 3-5% post-news pullback; hold 3-6 months for a re-rate into product-catalyst season. Risk/reward is favorable if the market starts valuing TXG as a multiomics platform rather than a single-product story.
• Pair trade: long TXG / short ILMN over 1-3 months. Thesis: TXG has clearer platform optionality and tighter strategic integration of proteomics, while ILMN faces a tougher burden to prove spatial differentiation; stop if ILMN announces a materially superior ecosystem partnership.
• Sell cash-secured puts on TXG at strikes ~10-15% below spot with 45-60 day tenor. You get paid to own a quality re-rate candidate while defining downside in case the market keeps punishing growth tools on valuation.
• Avoid chasing ILMN upside until there is evidence of customer adoption, not just product announcements. The trade-off is that ILMN may need several quarters to prove commercialization, so the better risk-adjusted expression is relative value, not outright long.
• Treat MSFT as a sentiment-driven hedge only if AI headlines keep pressuring the group; use short-dated calls or puts tactically rather than a directional core position, since the impact on tools demand is indirect and likely lagged.